Publication
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerExtramammary Paget Diseasecivic_curation1.00
- cancerMalignant Breast Neoplasmcivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugAfatinibcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 Activating Mutationcivic_curation1.00
- variantERBB2 D769Ycivic_curation1.00
- variantERBB2 S310Fcivic_curation1.00
- variantERBB2 V777Lcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35939768
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 D769Y2 | ||||||||
| Afatinib | Extramammary Paget Disease | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11688In this phase II NCI-MATCH trial, a patient with extra-mammary Paget disease of the skin with ERBB2 D769Y mutation was treated with afatinib. A confirmed RECIST response was reported in the patient wh… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC | civic |
| 〃 | Peritoneal CarcinomaUNRESOLVED | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11689In this phase II NCI-MATCH trial, a patient with primary peritoneal carcinoma with ERBB2 D769Y mutation was treated with afatinib. A RECIST response was reported in the patient, however, it wasn't con… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC | civic |
| ERBB2 S310F1 | ||||||||
| Afatinib | Malignant Breast Neoplasm | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11691In this phase II NCI-MATCH trial, a patient with ER+ lobular breast cancer with ERBB2 S310F mutation was treated with afatinib. A 51% reduction of RECIST target lesions was reported after six cycles, … (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC | civic |
| ERBB2 V777L1 | ||||||||
| Afatinib | Malignant Breast Neoplasm | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11690In this phase II NCI-MATCH trial, a patient with ER+ invasive ductal breast cancer with ERBB2 V777L mutation was treated with afatinib. A RECIST response was reported in the patient, however, it wasn'… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC | civic |
| ERBB2 Activating Mutation1 | ||||||||
| Afatinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11676In this phase II NCI-MATCH trial, 40 patients with ERBB2 SNVs or ERBB2 insertions/deletions were treated with afatinib. The ORR was 2.7% (90% CI, 0.14-12.2). 37.8% of the patients had SD as the best r… (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC | civic |